Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease